Candel Therapeutics

Company snapshot

Candel ($CADL) is a clinical stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. Candel has established two clinical stage multimodal biological immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV)

• 12 active pipeline program(s) linked via ClinicalTrials.gov.
• 12 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Candel Therapeutics. Not investment advice.

• approval Jun 2, 2026

  Candel's Prostate Cancer Drug: Long-Term Data Insights Ahead of FDA Filing

• Peer + 0 momentum

  United Therapeutics Europe

  TA overlap score 40

• Peer + 0 momentum

  Oncolytics Biotech

  TA overlap score 24.6

Recent activity

Latest pipeline, patent, and corporate events for Candel Therapeutics.

1. Jun 8, 2026 Clinical update

   CAN-2409 + valacyclovir — Phase 1

2. Jun 8, 2026 Clinical update

   aglatimagene besadenovec + valacyclovir — Phase 2

3. Jun 8, 2026 Clinical update

   Aglatimagene besadenovec + valacyclovir — Phase 3

4. Jun 8, 2026 Clinical update

   AdV-tk + valacyclovir — Phase 1

5. Jun 5, 2026 Clinical update

   rQNestin — Phase 1

View all clinical trial activity →

• What is Candel Therapeutics?

  Candel Therapeutics is a biotech organization headquartered in Needham, USA. It trades on NYSE under ticker CADL. Primary therapeutic focus areas include Malignant Glioma, Prostate Cancer, Glioma, Malignant, Pancreatic Adenocarcinoma, Malignant Pleural Effusion. NovaPharmaNews li

• Is Candel Therapeutics publicly traded?

  Yes. Candel Therapeutics is listed with ticker CADL on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Candel Therapeutics develop or market?

  We link 4 drug profile(s) where Candel Therapeutics is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/candel-therapeutics#company-drugs.

• What are the latest developments for Candel Therapeutics?

  In the last 12 months our linked public records show 12 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Candel Therapeutics focus on?

  Candel Therapeutics focuses on Malignant Glioma, Prostate Cancer, Glioma, Malignant based on our analysis of their pipeline programs and drug development activities.